4-[2-(3,4-Dimethylphenoxy)ethyl]morpholine

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯酚醚
• 英文名称: 4-[2-(3,4-Dimethylphenoxy)ethyl]morpholine
• 化学式: C₁₄H₂₁NO₂
• mdl: MFCD01308601
• 分子量: 235.32
• InChiKey: FOGHINOQQGKSDD-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  2.3
• 重原子数：
  17
• 可旋转键数：
  4
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.571
• 拓扑面积：
  21.7
• 氢给体数：
  0
• 氢受体数：
  3

文献信息

• BENZIMIDAZOLES AND RELATED ANALOGS AS SIRTUIN MODULATORS
  申请人：Vu Chi B

  公开号：US20110124637A1

  公开（公告）日：2011-05-26

  Provided herein are sirtuin-modulating compounds of formula (II). The sirtuin-modulating compounds may be used for increasing the lifespan of a cell, and treating and/or preventing a wide variety of diseases and disorders including, for example, diseases or disorders relating to aging or stress, diabetes, obesity, neurodegenerative diseases, cardiovascular disease, blood clotting disorders, inflammation, cancer, and/or flushing as well as diseases or disorders that would benefit from increased mitochondrial activity. Also provided are compositions comprising a sirtuin-modulating compound in combination with another therapeutic agent.

  本文提供的是公式（II）的sirtuin调节化合物。这些sirtuin调节化合物可用于延长细胞寿命，并治疗和/或预防各种疾病和疾患，包括与衰老或压力有关的疾病或疾患、糖尿病、肥胖症、神经退行性疾病、心血管疾病、血液凝块疾病、炎症、癌症和/或潮红，以及需要增加线粒体活性的疾病或疾患。还提供了包含sirtuin调节化合物与另一种治疗剂的组合物。
• TRICYCLIC COMPOUNDS ACTING ON CRBN PROTEINS
  申请人：Chia Tai Tianqing Pharmaceutical Group Co., Ltd.

  公开号：EP3848367A1

  公开（公告）日：2021-07-14

  The present invention discloses a series of tricyclic compounds and use thereof in preparing a medicament for treating a disease related to CRBN protein. Specifically, the present invention discloses a derivative compound of formula (1) or a pharmaceutically acceptable salt thereof.

  本发明公开了一系列三环化合物及其在制备治疗 CRBN 蛋白相关疾病的药物中的用途。具体而言，本发明公开了一种式（1）的衍生物化合物或其药学上可接受的盐。
• Fused heteroaryl derivatives
  申请人：Hayakawa Masahiko

  公开号：US20070037805A1

  公开（公告）日：2007-02-15

  The present invention provides a pharmaceutical composition which is useful as a phosphatidylinositol 3 kinase (PI3K) inhibitor and an antitumor agent, and it provides a novel bicyclic or tricyclic fused heteroaryl derivative or a salt thereof which possesses an excellent PI3K inhibiting activity and cancer cell growth inhibiting activity.
• FUSED HETEROARYL DERIVATIVES
  申请人：HAYAKAWA Masahiko

  公开号：US20100137584A1

  公开（公告）日：2010-06-03

  The present invention provides a pharmaceutical composition which is useful as a phosphatidylinositol 3 kinase (PI3K) inhibitor and an antitumor agent, and it provides a novel bicyclic or tricyclic fused heteroaryl derivative or a salt thereof which possesses an excellent PI3K inhibiting activity and cancer cell growth inhibiting activity.
• US7173029B2
  申请人：——

  公开号：US7173029B2

  公开（公告）日：2007-02-06